Since graft-versus-leukemia (GVL) is the main weapon for disease eradication after reduced intensity conditioning (RIC) allogeneic SCT, the availability of sensitive and specific techniques to monitor changes in tumor load after transplant are especially helpful. These minimal residual disease techniques would allow an early intervention in the event of low tumor burden, for which immunotherapy is highly effective. Some authors have found an association between persistence of MRD, mixed chimerism and risk of relapse. Nevertheless, data from the literature remain contradictory and further correlations should be established, especially in RIC transplants. In this study we have analyzed the impact of MRD and chimerism monitoring on the outcome of 34 patients undergoing RIC allogeneic SCT who were considered poor candidates for conventional transplantation due to advanced age or other concurrent medical conditions. At day +100 25 (75%) patients reached complete remission (CR), there were five (15%) partial responses and three patients progressed. Incidence of grade 2-4 aGVHD and extensive cGVHD were 35% and 58%, respectively. Sixteen percent of patients developing aGVHD relapsed as compared to 47% in those without aGVHD (P = 0.03) and also 10% of patients developing cGVHD relapsed as compared to 50% relapses in those without cGHVD (P = 0.03). Four patients (12%) died due to early (n = 1) and late (n = 3) transplant-related mortality. After a median follow-up of 15 months, 24 out of the 34 patients remain alive. Projected overall survival and disease-free survival at 3 years are 68% and 63%, respectively. Early chimerism analysis showed 67% of patients with complete chimerism (CC) in bone marrow (BM), 86% in peripheral blood (PB), 89% in granulocytes and 68% in T lymphocytes. On day +100, these figures were 68%, 79%, 90% and 73%, respectively, and on day +180 there were 83% patients with CC in BM, 100% in PB, 100% in granulocytes and 100% in T lymphocytes. We observed a trend to a higher incidence of relapse in patients with mixed chimerism (MC) as compared to patients with CC. MRD monitoring by flow cytometry and/or RT-PCR analysis was performed in 23 patients. MRD assessment on days +21 to +56 after transplant allowed identification of patients at risk of relapse. In this sense, seven out of 12 patients (58.3%) who had positive MRD on days +21 to +56 relapsed as compared to none out of 11 patients who had negative MRD (P = 0.002). Of the seven patients with criteria to monitor MRD who relapsed after transplant, all but one remained MRD positive until relapse. By contrast, 10 patients remained MRD negative and all of them are in continuous CR. In nine additional patients, persistence of MRD or mixed chimerism was observed after transplant and withdrawal of cyclosporin with or without DLI was performed. Only two out of these nine patients relapsed. MRD clearance was preceded by CC and GVHD. In conclusion, in our study we found that RIC allogeneic transplantation can be used in patients considered poor candidates for conventional transplantation due to advanced age or other concurrent medical conditions with both low toxicity and low transplant-related mortality. Simultaneous studies of both chimerism and MRD are a useful tool in order to predict risk of relapse in patients undergoing RIC transplants and so can be helpful for individualizing treatment strategies after transplant.
Introduction
The use of myeloablative doses of chemotherapy followed by rescue with allogeneic stem cell transplantation (SCT) has been extensively used in patients with advanced hematological malignancies. Nevertheless, transplant-related mortality (TRM) is still rather high (ranging from 20 to 40%). [1] [2] [3] The ability of allogeneic SCT to eradicate leukemia is determined by both the intensity of the conditioning regimen and the graft-versus-leukemia (GVL) reaction, defined as the anti-leukemic effect mediated by immune cells of donor origin. 4 The efficacy of donor lymphocyte infusion (DLI) in patients failing other therapeutic strategies suggests that GVL could be a strong tool against tumor cells of hematopoietic origin. This evidence prompted the development of reduced intensity conditioning (RIC) regimens [5] [6] [7] designed to be immunosuppressive rather than myeloablative in an effort to reduce the toxicity and TRM associated with high-dose chemotherapy but maintaining the GVL effect.
Since GVL is the main weapon for disease eradication after RIC allogeneic SCT, 5 the availability of sensitive and specific techniques to monitor changes in tumor load 8 after transplant will be especially helpful. These minimal residual disease (MRD) techniques would allow an early intervention in the event of a low tumor burden, for which immunotherapy is highly effective, as suggested by the increased probability for achieving remission in CML patients in cytogenetic or molecular relapse after conventional transplantation as compared to chronic or accelerated phase relapses. [9] [10] [11] [12] [13] [14] In addition, data exist which suggest that patients with chronic or accelerated phase disease require more donor lymphocytes to achieve remission than patients treated in cytogenetic or molecular relapse, 15 so that the former patients are at a higher risk of developing DLI-related toxicity such as GVHD or secondary aplasia. In this sense, the timing and dosage of DLI should be adapted to the tumor response measured by sensitive and specific techniques.
Some authors have found an association between persistence of MRD, mixed chimerism and risk of relapse, especially in T cell-depleted BMT. 16, 17 Nevertheless, data from the literature remain controversial since other studies do not find this correlation. 18 Even more, with the increased sensitivity of new detection methods, mixed chimerism has been found to be more frequent than initially thought, especially in RIC or T cell-depleted transplants 19, 20 so that this correlation should be further clarified, especially in RIC transplants.
In this study we have analyzed the impact of MRD monitoring on the outcome of 34 patients undergoing RIC allogeneic SCT. In addition, we have investigated the relationship between MRD and persistence of host-derived hematopoietic cells assessed by chimerism analysis.
Patients and methods

Patient characteristics
Between May 1998 and April 2001, 34 patients were treated at the University Hospital of Salamanca (Spain) using a RIC PBSCT from a related donor. Patients' characteristics are specified in Table 1 . All but one were HLA matched. Eligibility criteria included patients with a hematological malignancy potentially curable with an allogeneic transplantation but who were considered to have a high mortality risk due to advanced age, relapse after a previous transplant or any other pre-transplant condition specified in Table 1 . Patients gave written informed consent for inclusion in the protocol, which was approved by the local ethical review board and the Spanish Drug Agency (protocol 99-0151).
Median age was 52 years, ranging from 25 to 67. Thirteen patients (38%) had received a prior transplant (3 allogeneic, 10 autologous). Disease status at transplant was categorized as early in 12 cases (acute leukemia or poor-risk myelodysplasia in first complete remission, untreated good-risk myelodysplasia, first chronic-phase CML, lymphoid malignancy in first remission), intermediate in 13 patients (acute leukemia or myelodysplasia in second or higher complete remission, second chronic-phase CML, lymphoid malignancy in second or higher complete remission or partial response) and advanced in nine cases (refractory or relapsed disease).
Treatment plan and supportive care
Two RIC regimens were used, one for lymphoid and one for myeloid malignancies. The lymphoid RIC regimen consisted of fludarabine 30 mg/m 2 intravenously (i.v.) on days −8 to −4 followed by melphalan 70 mg/m 2 i.v. on days −3 and −2. The myeloid regimen consisted of fludarabine 30 mg/m 2 i.v. on days −9 to −5 and busulphan 1 mg/kg × 10 doses (days −6 to −4, total 10 mg/kg), with phenytoin given as anticonvulsant prophylaxis. Filgrastim-stimulated peripheral blood stem cells were infused on day 0, for a target dose of у4 × 10 6 CD34 + cells/kg recipient body weight. GVHD prophylaxis consisted of cyclosporine A (CsA) plus short-course methotrexate (MTX). CsA was given at a dose of 0.5 mg/kg twice a day i.v. from day −7 to −2, and then 1.5 mg/kg twice a day i.v. from day −1. Oral CsA was started as soon as possible. Levels were maintained in the therapeutic range until tapering. In the event that acute GVHD grade ϾI did not develop, CsA was tapered 10% weekly starting on day +90 and discontinued by day +180. A faster taper was scheduled in patients considered at risk of relapse (positive MRD or persistence of MC) if no GVHD had previously flared. MTX was given at a dose of 10 mg/m 2 i.v. on days +1, +3 and +6, followed by folinic acid rescue at a dose of 10 mg i.v. every 6 h for four doses starting 24 h after each dose of MTX.
Infectious prophylaxis consisted of fluconazole 400 mg every day until day +75, standard-dose acyclovir (800 mg p.o. twice a day or 250 mg/m 2 i.v. twice a day), and Bactrim 2 days per week from engraftment and until day +180 if no GVHD had flared. CMV antigenemia was monitored at least once weekly during the first 3 months post transplant and then as clinically indicated. Febrile neutropenia was managed with broad-spectrum antibiotics according to institutional protocols. Acute GVHD уgrade 2 was treated with 6-metil-prednisolone at 2 mg/kg/day, with subsequent tapering in responsive cases. Refractory GVHD was treated with antilymphocyte globulin or other salvage regimens.
Chimerism analysis and minimal residual disease monitoring
Chimerism studies:
After transplant, serial samples of whole peripheral blood (PB), bone marrow (BM) and CD3 + and CD15 + selection cells obtained using magnetic microbeads according to the manufacturer's protocol (MACS cell separation; Miltenyi Biotec, Gladbach, Germany) were analysed for degrees of donor-recipient chimerism using PCR of informative minisatellite regions. Samples were routinely analyzed soon after hematological recovery (day +21 to +56), on day +90 to +100 and on day +180 to +200, and then every 3 months or in cases of disease recurrence or suspicion of graft failure. Chimerism studies were performed with a commercially available automated kit (AmpFlSTR, SGM Plus; Applied Biosystems, Norwalk, CT, USA). This kit uses multiplex amplification of 10 short tandem repeat loci (STR) (D3S1358, VWA, D16S539, D2S1338, D8S1179, D21S11, D18551, D19S433, THO1 and FGA) plus the gender marker Amelogenin. PCR of the STR regions were performed using 2-5 ng of genomic DNA in a final volume of 25 l. In brief, 4 l of the PCR product were mixed with 4 l of deionized formamide, 1 l of loading buffer (Applied Biosystems Foster City, CA, USA) and 0.5 l of the specific molecular marker (GeneScan 500 ROX; Applied Biosystems). This mixture was then warmed for 3 min at 95°C and 1.5 l of this was loaded in a 5% polyacrylamide denaturing gel with urea placed in a 377 DNA automated sequencer (Applied Biosystems). The electrophoresis was made on 0.5× Tris-Borate EDTA (TBE) buffer for 2.5 h at 3000 V. The quantification of the fluorescence and the calculation of the precise DNA fragment size was made with the 'GeneScanT software' (Applied Biosystems). Gel preferences were multicomponent gel image, estimated maximum peak high of 1000 and confidence threshold of 50%. The analysis preferences included: (1) analysis range: full; (2) size call range: all sizes; (3) data processing: baseline, multicomponent and smooth options light; (4) size calling method: local southern; (5) peak detection with min. peak half width: 3 pts; and (b) split peak correction: none. The remaining parameters were used by default. In order to calculate the percentage of mixed chimerism (MC), defined as presence of patient's hematopoiesis у3%, we used the following formula: % donor peak area = [ (A D1 + A D2 ) / (A D1 + A D2 + A p1 + A p2 ) ] × 100 where A is peak area; D is donor allele(s); and p is patient allele(s). In the cases in which patient and donor shared an allele, we decided to use only the informative alleles (those that allow us to distinguish the patient from the donor). Generally, we had several STR with informative alleles. In theses cases, we calculated a median of percentages to determine the result. A more detailed description of this procedure has recently been reported. 21 
Minimal residual disease monitoring by PCR:
Details on processing of bone marrow and/or peripheral blood samples and RT-PCR protocols have been given in previous reports. 22, 23 The mRNA quality was always assessed in all cases by RT-PCR amplification of the ABL transcript. The RT-PCR amplification of M-BCR/ABL (two cases) and mBCR/ABL (two cases) fusion transcripts were performed according to the primers, protocols and criteria of the European 'BIOMED 1 Concerted Action for standardization of MRD studies in acute leukemia'. 22 All assays were carried out at least twice, using appropriate positive (cDNA from the K562 and Tom-1 cell lines) and negative controls (cDNA from a healthy donor and H 2 O). PCR products were electrophoresed on 2% NuSieve agarose gels and visualized by ethidium bromide staining under UV light.
Minimal residual disease monitoring by flow cytometry:
Antigenic expression on tumoral cells at diagnosis was systematically analyzed by multiparametric flow cytometry (FACScan, Becton Dickinson Biosciences, San José, CA, USA) using triple stainings with different fluorochrome-conjugated (FITC, PE, PerCP or PE-Cy5) MoAb combinations according to the type of disease, as previously described, [24] [25] [26] [27] in order to identify phenotypic aberrancies that could be used, later on, as 'custom-built' probes for detection of residual tumoral cells displaying the same phenotypic profile in the BM in morphological CR. Only those MoAb combinations selected at diagnosis as informative for MRD studies were used. In addition, to increase the sensitivity of the analysis, data acquisition in the flow cytometer was performed in two consecutive steps. Briefly, in the first step, acquisition of all cells present in the sample was performed and at this point at least 15 000 events/tube were measured. Subsequently, in a second step, a multiparametric livegate was used to acquire more data on neoplastic cells which were potentially present in low numbers within the original BM sample. For that purpose, acquisition through a SSC/antigen live gate was performed and information was collected for at least 10 6 BM nucleated cells. Data analysis was based on the identification of cells with identical aberrant phenotypic features to those of tumoral cells at diagnosis.
For data acquisition, the LYSIS II or Cell Quest software programs (Becton Dickinson) were used. The PAINT-A-GATE PRO software program (Becton Dickinson) with the polynomial SSC transformation capability was used for further data analysis. Analysis was performed on gated blast cells according to previously defined methods.
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Statistical analysis
Comparison of relapse rate between groups was performed by using the chi square test and Fisher's exact test. All events analyzed were calculated from the time of transplantation using Kaplan-Meier product-limit estimates. For TRM patients alive without progression were censored at last follow-up, while those who suffered disease progression were censored at progression. Disease-free survival (DFS) was calculated from transplant until disease progression, and patients who suffered TRM and those who were still alive without progression at the time of reporting were censored at death and last follow-up, respectively. Overall survival (OS) was calculated from transplant until death from any cause, and surviving patients were censored at last follow-up. The incidence and time to onset of chronic GVHD were calculated in patients followed for at least 90 days.
Results
Clinical outcome
Both RIC regimens were well tolerated. Two patients developed diarrhea уgrade 3, seven patients mucositis уgrade 3 and one patient nausea уgrade 3. All patients engrafted. Median days post-transplant to reach Ͼ500 granulocytes/mm 3 and Ͼ20 000 platelets/mm 3 were +12 and +11, respectively. Median of days with Ͻ100 and 500 granulocytes/mm 3 were 7 (range 0 to 14 days) and 13 (range 7 to 27 days), respectively and median of days with Ͻ20 000 platelets/mm 3 was 3 (range 0 to 15 days). Incidence of acute graft-versus-host disease (aGVHD) grade 2-4 was 35%, with eight patients developing grade 2 aGVHD and one patient grade 3. Incidence of extensive chronic GVHD was 58%. Four patients (12%) died due to early (n = 1) and late (n = 3) TRM (Table 1) . Cause of death was fungal infection in three patients and bronchiolitis obliterans in one patient.
Response to transplant was evaluated between days 80 and 100. At that time 25 (75%) patients were in complete remission (CR), there were five (15%) partial responses and three patients progressed prior to that date. One patient was not evaluated due to early TRM.
Six out of nine patients transplanted with advanced disease reached CR (two subsequently relapsed), one reached partial response and two patients progressed. Currently, five out of these nine patients are in maintained CR or PR. Upon considering the 13 patients categorized as intermediate disease status, nine reached CR (one patient relapsed later) and four PR (three patients relapsed later). Finally, 10 out of 12 patients transplanted in early disease status are in maintained CR.
Overall, eight patients have relapsed (23%). Of these eight patients, two received RIC transplant in relapse after a conventional allogeneic transplant and one of them is in CR after third allogeneic infusion, another patient reached CR after local radiotherapy and DLI and two are receiving DLI. Four out of these eight patients have died.
Concerning the relationship between GVHD and relapse rate, two out of 12 patients developing aGVHD relapsed (16%) as compared to seven relapses in 15 patients (46.6%) without aGVHD (P = 0.03). Also, only two out of 19 patients developing cGVHD relapsed as compared to six out of 12 patients without cGVHD (10.5% vs 50%, P = 0.03).
After a median follow-up of 15 months, 24 out of the 34 patients are alive. Median disease-free and overall survival has not been reached. Projected OS and DFS at 3 years are 68% and 63%, respectively (Figures 1 and 2) .
Chimerism studies
Chimerism analysis performed on days +21 to +56 (early chimerism) showed 67% of patients with complete chimerism (CC) in bone marrow (BM), 86% in peripheral blood (PB), 89% in granulocytes and 68% in T-lymphocytes. On day +100, these figures were 68%, 79%, 90% and 73%, respectively, and on day +180 there were 83% patients with CC in BM, 100% in PB, 100% in granulocytes and 100% in T lymphocytes (Table 2 ). Overall survival.
Figure 2
Disease-free survival.
Concerning relapse rate we observed a trend of a higher incidence of relapse in patients with mixed chimerism as compared to patients with complete chimerism. In this sense, only three out of 13 (23%) patients with early CC in T lymphocytes relapsed as compared to two out of six (33%) patients with mixed chimerism (MC). No clear relationship was found between relapse and chimerism in other different subsets. Nevertheless, as specified later, in nine patients a fast taper of CsA was performed due to persistence of MRD (n = 3), mixed chimerism (n = 2) or both (n = 4). Of these nine patients, six developed cGHVD and none of these relapsed as compared to two relapses out of the three patients who did not develop cGVHD.
As far as GVHD was concerned, CC was associated with a higher incidence of GVHD as compared to MC. Accordingly, 20% of patients with early MC in BM developed acute GVHD as compared to 42% of patients with CC (P = 0.2). Similar results were found when we analyzed early chimerism in peripheral blood (0% vs 35% for patients with MC vs CC developed aGVHD, respectively; P = 0.1), granulocytes (aGVHD in 0% vs 44% of patients with MC vs CC, P = 0.2) and in T lymphocytes (aGVHD in 17% vs 50% of patients with MC vs CC, P = 0.1). No clear relationship was found between chronic GVHD and chimerism status on days +100 and +180. It is worthwhile mentioning that, as previously described, in six patients showing mixed chimerism a fast taper of CsA was performed so that it could increase the risk of cGVHD in these patients.
Leukemia
Minimal residual disease monitoring
In 23 out of 34 patients it was possible to monitor MRD by flow cytometry or RT-PCR. In 10 patients MRD studies were constantly negative (absence of abnormal cells at the detection limit of the technique (10 −5 )) and all of them are in continuous complete remission (Table 2) . Among these patients three had mixed chimerism in some (n = 2) or all subsets analyzed (n = 1) and a progressive increase in donor hematopoiesis was observed, although in the former patient immune manipulation was performed as specified latter on.
Regarding the patients in progression (n = 2) or relapse (n = 8) after transplant, seven of them had criteria to monitor MRD by flow cytometry. All but one remained MRD positive by flow cytometry until morphological/clinical relapse ( Table  2 ). Only one patient diagnosed with MM had a negative MRD by flow cytometry in the study performed prior to relapse. Three patients did not have suitable markers for MRD monitoring: one of them was a NHL patient who developed an extramedulary relapse, another patient had a CMML and relapsed as a secondary acute myeloid leukemia and the remaining patient had a refractory HD and progressed soon after transplant.
In nine patients, a fast taper of cyclosporin was performed due to persistence of MRD and MC (n = 4), MRD (n ϭ 3) or mixed chimerism (n = 2). Two CML patients (3178, 3253) with MC and persistence of BCR-ABL + developed complete chimerism (CC) after CsA taper and DLI. Both patients became BCR-ABL negative 3 to 4 months after DLI. One Ph + ALL patient (3066) refractory to prior chemotherapy became CC and BCR-ABL negative after CsA taper. In four patients diagnosed with multiple myeloma (2989, 3226, 3058, 2968) a fast taper of CsA and DLI was scheduled due to persistence of myelomatous plasma cells assessed by flow cytometry and serum monoclonal Ig (and MC in patient 2989). Although a slow decrease in the amount of monoclonal component was initially observed, two of them have finally relapsed. Interestingly, none of these relapsing patients developed GVHD. Finally, in two patients diagnosed with AML and MDS immune manipulation was performed due to the persistence of mixed chimerism in all subsets analyzed although MRD was negative (1656) or not evaluated (1493). After a fast taper of CsA complete chimerism was achieved in both patients. It is worthwhile mentioning that MRD clearance was preceded by full donor chimerism. In addition, six out of these nine patients developed extensive cGVHD and GVHD preceded MRD clearance. Three patients who did not develop GVHD relapsed (n = 2) or remained MRD positive (n = 1).
Finally, seven out of 12 patients (58.3%) who had positive MRD on days +21 to +56 relapsed as compared to 0 out of 11 patients who had a negative MRD study (P = 0.002).
Discussion
The high mortality rate reported after allogeneic transplantation in most series of patients with advanced age or co-morbid pre-transplant conditions [28] [29] [30] [31] prompted several groups to develop new approaches, such as reduced intensity conditioning (RIC) regimens. [5] [6] [7] 32 The low TRM observed in our series of patients (12%) is in accordance with previous studies that also used RIC, and showed a TRM ranging from 11% to 37% 33, 34 using related or unrelated donors. Nevertheless, these favorable results could be hampered by a higher risk of relapse since the efficacy of this type of trans- All patients with more than 1 year of follow-up are in maintained CR with negative MRD and CC.
plant relies mainly on the graft-versus-leukemia effect. In this sense, it should be important to monitor closely these patients in order to identify patients at risk of relapse when there is a low tumor burden situation where immunotherapy reaches its higher efficacy as shown in some studies 10, 12, 15, 35 and therapeutic approaches such as DLI can be designed to decrease toxicity, by using lower doses of T cells and the most appropriate timing for infusion. 15, 36 Persistence of mixed chimerism has been associated with a higher incidence of relapse in conventional allogeneic transplantation with 15, 16 or without 37, 38 T cell depletion. Persistence of recipient hematopoiesis is a common finding after RIC allogeneic transplant as shown in several studies 5, 33, 39 and could also be associated with a higher incidence of relapse in this type of transplant. Nevertheless, several investigators suggest that transient MC may be of some benefit since it is related to a lower incidence of GVHD. In this sense, it has been suggested that minimally cytotoxic pretransplantation conditioning allows persistence of host antigen-presenting cells, thus enhancing presentation of host minor antigens to donor T cells and initiation of GVL and GVHD. 39, 40 Our results are in accordance with this hypothesis, although higher numbers of patients are required to confirm this statement. Accordingly, transient MC could be a useful tool to modify GVHD but it will be important to differentiate between those patients with normal or malignant residual host hematopoiesis, so that immunotherapy could be initiated only in patients at high risk of relapse due to residual leukemia, avoiding toxicity in patients at low risk. In this sense, molecular monitoring of MRD has been shown as a useful approach, particularly in CML and ALL patients who undergo conventional allogeneic transplantation. 41, 42 Unfortunately, molecular markers for MRD investigations are not available for all hematological malignancies. Immunophenotyping analysis by multiparametric flow cytometry can be an attractive alternative in those cases [24] [25] [26] [27] and could contribute in increasing the number of patients for monitoring after transplant. In the present study, none of the 11 patients with negative MRD at days +21 to +56 relapsed as compared to seven relapses out of 12 patients with positive MRD. Interestingly, GVHD prophylaxis was shortened and/or DLI administered in all five patients who were MRD positive and did not relapse. In addition, as reported by Childs et al, 43 we found that MRD clearance was preceded by full donor chimerism and GVHD suggesting that chimerism is an important factor determining GVHD and GVL. By contrast, we did not find that T lymphoid chimerism precedes myeloid engraftment although in our study the number of chimerism analysis during the first 3 months was more limited.
In this study we found a 35% and 58% incidence of acute and extensive chronic GVHD, respectively. This incidence does not seem significantly different as compared to other studies where peripheral blood stem cells have been used as the source of progenitors in conventional allogeneic transplantation. 44, 45 Nevertheless, this comparison is difficult since median age is higher in our subgroup of patients as compared to those undergoing conventional allogeneic PBSCT and incidence of GVHD increases with age. 46 Some researchers have reported a lower incidence of acute and chronic GVHD by adding CAMPATH-1 to the RIC. 32 However, in our study we found a lower relapse rate in patients developing GVHD, so that it is important to balance the risk/benefit of decreasing GVHD through different therapeutic interventions vs an increase in the risk of relapse. 11 Thus, longer follow-up is required to establish the efficacy of these different approaches.
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On the other hand, our results show that fludarabine-based regimens induce complete chimerism and ATG is not necessary for avoiding graft failure although ATG probably plays a role in GVHD prophylaxis so that comparison with conventional MTX would require further studies.
In conclusion, in our study we found that RIC allogeneic transplantation can be used in patients considered poor candidates for conventional transplantation due to advanced age or other concurrent medical conditions with both low toxicity and low TRM. Our results are in accordance with previous studies suggesting that withdrawal of immunosupression and/or DLI in patients with increasing mixed chimerism may prevent hematological relapse. 47 Thus, simultaneous studies of both chimerism and MRD present a useful tool for the prediction risk of relapse in patients undergoing RIC transplants and could therefore prove helpful for individualizing treatment strategies after transplant.
